Bluejay Diagnostics, Inc. has officially executed a 1-for-4 reverse stock split of its common stock, effective as of November 3, 2026. This strategic move is aimed at increasing the company's stock price, which may enhance its appeal to institutional investors and improve overall market perception.

The decision for the reverse stock split was made following the approval from stockholders at the Annual Meeting held on June 9, 2026. The Board of Directors selected the 1-for-4 ratio, which reduces the number of issued and outstanding shares from approximately 4.47 million to about 1.12 million shares. The company’s stock continues to trade under the symbol "BJDX" on the Nasdaq.

Background

Bluejay Diagnostics, Inc. operates within the surgical and medical instruments and apparatus industry, as classified under SIC code 3841. The company is listed on the Nasdaq under the ticker symbol BJDX. As an emerging growth company, Bluejay focuses on innovative diagnostic solutions that aim to improve patient care.

What the Filing Says

According to the SEC filing, "On October 30, 2026, the Company filed a certificate of amendment to the Charter... to implement a 1-for-4 reverse split of the Company’s common stock." This move is designed to consolidate shares and potentially elevate the stock price.

Impact

The reverse stock split is expected to affect existing shareholders, as it consolidates their shares into fewer units while maintaining the overall value of their investment. Additionally, this action may attract institutional investors who often prefer stocks with higher prices and lower share counts, potentially leading to increased liquidity.

What's Next

The filing does not say what happens next. However, the company will likely continue to focus on its growth strategy and may provide further updates in future filings.